Purpose Guidance on use of GDMT following left ventricular assist device (LVAD) remains scant despite studies showing optimal use may reduce morbidity and mortality. We aimed to evaluate the impact of an LVAD OPTIMIZE clinic on medication utilization and outcomes. Methods A multidisciplinary clinic composed of advanced practice providers, pharmacists, nutritionists, and nurses was developed and enrolled patients after discharge from LVAD implantation. Candidates for enrollment were those who could make the scheduled visits. Our OPTIMIZE clinic consisted of a total of 6 visits each two weeks apart and included medication optimization as well as nutrition and pharmacy counseling. Patients who survived to discharge and were not enrolled in the OPTIMIZE clinic were utilized as controls and their variables were collected approximately 3-4 months post-implant. T-test, Chi square, and negative binomial regression were utilized to compare variables and outcomes between groups. Results From January 2019 and March 2021, 26 patients completed OPTIMIZE clinic. Our control group consisted of 43 LVAD patients. Enrolled patients had an average age of 55.3 (±12.8) years, 11 (42.3%) were female, 24 (92.3%) were HeartMate 3 and 2 (7.8%) were HeartWare, and were enrolled an average of 38 (±16) days post-implant. At the end of OPTIMIZE, there was a 150% increase in beta blocker use (8 vs 20), 140% increase in ARNi use (5 vs 12), 17% increase in aldosterone antagonist use (18 vs 21), 41% reduction in loop diuretic use (17 vs 10), and 7 patients were started on SGLT2i (0 at baseline). Comparison of medication use, lab values, and hospitalizations at the end of LVAD OPTIMIZE clinic compared to controls at similar time points is shown in Table 1. Conclusion A multidisciplinary LVAD OPTIMIZE clinic can help improve medication utilization post-implant and is associated with lower rates of hospitalization and less renal dysfunction. Further studies are needed to help clarify optimal GDMT utilization and timing of initiation in this population. Guidance on use of GDMT following left ventricular assist device (LVAD) remains scant despite studies showing optimal use may reduce morbidity and mortality. We aimed to evaluate the impact of an LVAD OPTIMIZE clinic on medication utilization and outcomes. A multidisciplinary clinic composed of advanced practice providers, pharmacists, nutritionists, and nurses was developed and enrolled patients after discharge from LVAD implantation. Candidates for enrollment were those who could make the scheduled visits. Our OPTIMIZE clinic consisted of a total of 6 visits each two weeks apart and included medication optimization as well as nutrition and pharmacy counseling. Patients who survived to discharge and were not enrolled in the OPTIMIZE clinic were utilized as controls and their variables were collected approximately 3-4 months post-implant. T-test, Chi square, and negative binomial regression were utilized to compare variables and outcomes between groups. From January 2019 and March 2021, 26 patients completed OPTIMIZE clinic. Our control group consisted of 43 LVAD patients. Enrolled patients had an average age of 55.3 (±12.8) years, 11 (42.3%) were female, 24 (92.3%) were HeartMate 3 and 2 (7.8%) were HeartWare, and were enrolled an average of 38 (±16) days post-implant. At the end of OPTIMIZE, there was a 150% increase in beta blocker use (8 vs 20), 140% increase in ARNi use (5 vs 12), 17% increase in aldosterone antagonist use (18 vs 21), 41% reduction in loop diuretic use (17 vs 10), and 7 patients were started on SGLT2i (0 at baseline). Comparison of medication use, lab values, and hospitalizations at the end of LVAD OPTIMIZE clinic compared to controls at similar time points is shown in Table 1. A multidisciplinary LVAD OPTIMIZE clinic can help improve medication utilization post-implant and is associated with lower rates of hospitalization and less renal dysfunction. Further studies are needed to help clarify optimal GDMT utilization and timing of initiation in this population.